We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
167 result(s) found, displaying 31 to 40
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALHEMO concizumab 15 mg / 1.5 mL solution for injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALHEMO concizumab 300 mg / 3 mL solution for injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ALHEMO concizumab 60 mg / 1.5 mL solution for injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 3000 IU powder for injection vial with solvent.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 500 IU powder for injection vial with solvent.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 2000 IU powder for injection vial with solvent.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 1000 IU powder for injection vial with solvent.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ESPEROCT turoctocog alfa pegol 1500 IU powder for injection vial with solvent.
-
Australian public assessment report (AusPar)Alhemo (concizumab) is approved to prevent or reduce frequency of bleeding in patients who have haemophilia B with FIX inhibitors.
-
Prescription medicine registrationActive ingredients: Semaglutide.